Quark Biosciences
Taipei, Taiwan· Est.
Taiwan biotech delivering rapid, multiplex qPCR diagnostics for oncology, thyroid and infectious disease testing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech delivering rapid, multiplex qPCR diagnostics for oncology, thyroid and infectious disease testing.
OncologyEndocrinologyInfectious DiseasePrecision Medicine
Technology Platform
Proprietary chip‑based multiplex qPCR and digital PCR platform that enables simultaneous detection of up to 100 biomarkers with high tolerance for low‑quality samples.
Opportunities
Rapid, low‑cost multiplex diagnostics for oncology, endocrine and infectious disease markets; expansion into North America and Europe via regulatory clearances and strategic partnerships.
Risk Factors
Regulatory hurdles in major markets, intense competition from established IVD and NGS providers, and need to demonstrate assay performance parity with higher‑cost technologies.
Competitive Landscape
Competes with Roche cobas, Thermo Fisher QuantStudio, QIAGEN and Illumina NGS platforms; differentiation lies in ultra‑fast, high‑throughput chip‑based qPCR with low sample quality requirements.